Dimethandrolone dodecylcarbonate: Difference between revisions
CSV import |
CSV import |
||
| Line 24: | Line 24: | ||
{{pharm-stub}} | {{pharm-stub}} | ||
{{medicine-stub}} | {{medicine-stub}} | ||
<gallery> | |||
File:Dimethandrolone_dodecylcarbonate.svg|Dimethandrolone dodecylcarbonate | |||
</gallery> | |||
Latest revision as of 22:00, 16 February 2025
Dimethandrolone dodecylcarbonate (DDC) is a synthetic androgen and anabolic steroid (AAS) and a derivative of nandrolone. It is specifically a C17α alkylated, C7α carboxylated, C11β methylated, and C21 dodecylcarbonate ester of dimethandrolone (7α,11β-dimethyl-19-nortestosterone).
History[edit]
Dimethandrolone dodecylcarbonate was first described in a 2002 patent application by the University of Southern California. It was developed for potential use as a long-acting injectable male contraceptive and for the treatment of conditions such as hypogonadism, muscle wasting and osteoporosis.
Pharmacology[edit]
As an AAS, DDC is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). It has strong anabolic effects and moderate androgenic effects, which give it a favorable anabolic-to-androgenic ratio.
Side Effects[edit]
Potential side effects of DDC include virilization in women, gynecomastia in men, and cardiovascular and hepatic concerns. As with all AAS, it has potential for abuse and dependence.
See Also[edit]
References[edit]
<references />
-
Dimethandrolone dodecylcarbonate

